Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• KRAS mutations are prevalent in advanced colorectal cancer (CRC).
• KRAS G12C inhibitors are effective in non-small cell lung cancer but show limited efficacy in CRC due to resistance.
• Receptor tyrosine kinase (RTK) signaling activation is a key resistance mechanism.

Purpose of the Study:

• To evaluate the efficacy and safety of combining KRAS G12C inhibitors with epithelial growth factor receptor (EGFR) inhibitors in advanced CRC.
• To overcome resistance mechanisms associated with KRAS G12C inhibitor monotherapy.

Main Methods:

• Analysis of data from seven clinical trials (Phase I-III) investigating combinations of EGFR and KRAS G12C inhibitors.
• Focus on regimens like panitumumab plus sotorasib for KRAS G12C-mutated CRC.

Main Results:

• Combination therapy demonstrated overall response rates from 26% to 62.5%.
• Median progression-free survival ranged from 3.9 to 8.1 months.
• The combination regimen showed reasonable safety profiles.

Conclusions:

• Combining KRAS G12C inhibitors with EGFR inhibitors is more effective than monotherapy for KRAS G12C-mutated advanced CRC.
• Phase III trials are underway to establish these combinations as first or second-line treatments.
• Development of other KRAS inhibitors (G12D, pan-RAS) may expand treatment eligibility for advanced CRC patients.